Form 3 Filing by Xuebo Zeng

Xuebo Zeng, a director at CASI Pharmaceuticals, Inc., reported the acquisition of derivative securities on March 18, 2026. The filing details three option grants, all of which are fully vested and exercisable. The first option, with an exercise price of $1.93, gives the right to buy 11,231 Ordinary Shares and expires on April 14, 2033. The second option, exercisable at $2.67, also covers 11,231 Ordinary Shares and expires on June 18, 2034. The third option, with an exercise price of $1.26, pertains to 11,231 Ordinary Shares and has an expiration date of July 21, 2035. All holdings are reported as direct ownership.